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In silico clinical trials for pediatric 
orphan diseases
A. Carlier1,2,3, A. Vasilevich3, M. Marechal2,4, J. de Boer3 & L. Geris1,2
To date poor treatment options are available for patients with congenital pseudarthrosis of the tibia 
(CPT), a pediatric orphan disease. In this study we have performed an in silico clinical trial on 200 virtual 
subjects, generated from a previously established model of murine bone regeneration, to tackle the 
challenges associated with the small, pediatric patient population. Each virtual subject was simulated 
to receive no treatment and bone morphogenetic protein (BMP) treatment. We have shown that the 
degree of severity of CPT is significantly reduced with BMP treatment, although the effect is highly 
subject-specific. Using machine learning techniques we were also able to stratify the virtual subject 
population in adverse responders, non-responders, responders and asymptomatic. In summary, this 
study shows the potential of in silico medicine technologies as well as their implications for other 
orphan diseases.
Orphan diseases are defined as disorders with low prevalence (frequency of fewer than 6.5–10 patients in 10,000 
according to the WHO) and inadequate treatment strategies1. Although the general awareness has grown over the 
last three decades1, rare-disease research is faced with a number of specific challenges, such as the small number 
of trained disease experts, difficulties in obtaining research funding due to the limited economic impact, the geo-
graphic dispersion of patients which hampers patient recruitment for clinical trials and the need for specialized 
study designs to deal with the small patient cohorts, and high patient variability in the course of the disease2. 
Moreover, 50% of the patients affected by rare diseases are children3, which further complicates clinical research 
due to the uniqueness of children and particular ethical concerns4.
In order to tackle the challenges associated with rare diseases, specific incentives have been put into place to 
develop therapies, including amongst others tax credits, orphan product development grants and market exclu-
sivity (7 years in the USA, 10 years in the European Union and Japan, and 5 years in Australia)1,5. Unfortunately, 
the high failure rate of drug development, with less than 10% of new compounds that enter clinical trials ulti-
mately arriving to the market6,7, leads to high prices of orphan disease drugs and a significant socioeconomic bur-
den8. As such, the academic research community and the pharmaceutical industry are developing novel statistical 
methods for the design and analysis of small-population clinical trials9. Moreover, the use of in silico models and 
virtual clinical trials is increasingly being explored to understand the mechanisms underlying orphan diseases 
and to develop novel therapies10.
In silico models are abstract representations of complex systems in terms of equations or rules and a descrip-
tion of the region (spatially and/or temporally) on which the set of equations is valid11. Figure 1 gives a schematic 
overview of the modeling cycle, where the key components and biological processes are first formulated in a con-
ceptual model (here: cartilage production), which is then translated into a mathematical form. Note that in this 
example, cartilage is produced at a rate Pmc, which is a numerical value that can be tuned to represent normal or 
pathological chondrocyte behavior. In this way, computational models provide a tool to qualitatively and quanti-
tatively investigate both the individual and combined effects of various treatments on the rare disease phenotype. 
Moreover, computational models offer a practical, economical, and ethical alternative to in vivo experiments by 
testing a large set of different conditions (e.g., dosing and timing of administration) and selecting the most prom-
ising ones. Also, by tuning the rate Pmc (and other parameters in more extensive models), the in silico model can 
be personalized, each unique parameter set representing a unique, “virtual subject.” Since hundreds of different 
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parameter sets can be created in silico, a large cohort of virtual subjects can be established, overcoming the limita-
tion of small patient cohorts in rare diseases. Furthermore, the challenges associated with (pediatric) randomized 
clinical trials are avoided by using the in silico model to generate a unique paired data set of both treated and 
non-treated virtual subjects.
In this study we aim to combine data-driven and mechanistic modeling approaches to illustrate how in silico 
models can contribute to unraveling the mechanisms underlying orphan diseases, with a particular focus on 
congenital pseudarthrosis of the tibia (CPT) associated with mutations in Neurofibromatosis Type 1 (NF1). CPT 
is a rare disease which is characterized by a progressive bowing of the tibia and develops into spontaneous frac-
tures in the distal third of the tibia12. Typically the bone regeneration is insufficient, resulting in a pseudarthrosis, 
which is treated by physical excision of the abnormal bone tissue (called the ‘hamartoma’) and internal or external 
fixation12. In recent clinical practice, rhBMP-2 or rhBMP-7 (recombinant human bone morphogenetic protein) is 
used to enhance the surgical outcome. However, the effectiveness of BMP therapies is still highly debated13,14 and 
the FDA has issued a warning against the use of BMP in skeletally immature patients15. As such, the goal of this 
study is to assess the effect of BMP treatment in an extensive, investigative in silico clinical trial using a previously 
developed mechanistic model of murine bone regeneration16 and advanced machine-learning techniques to mine 
the large set of virtual subject data.
Results
The virtual clinical trial predicted the efficacy of treatment. The degree of severity of CPT was 
assessed by the complication index (CI), a linear combination of three phenotypic CPT symptoms (see Methods). 
A parameter combination yielding a small CI value reflects a fairly normal fracture-healing process with only 
minor aspects of CPT (if any). Conversely, a parameter combination resulting in a large CI value represents 
severely impaired fracture healing reminiscent of the CPT phenotype. The virtual clinical trial predicted a wide 
range of CI values, corresponding to different degrees of severity by which the pseudarthrosis presents itself, for 
both the treated and the non-treated group of subjects (Fig. 2A). The group of treated subjects was characterized 
by a significantly lower mean CI value (Fig. 2B, *p < 0.01) and a higher amount of bony unions (Fig. 2C), indicat-
ing a beneficial effect of BMP treatment.
The virtual clinical trial stratified subjects. To see whether the whole virtual subject population 
responded similarly to the BMP treatment, we plotted for each subject the results of the treatment versus no 
treatment (Fig. 2D). Using an arbitrary cut-off of CI value of 0.5, the virtual subjects clustered into four dis-
tinct groups: adverse responders (a low CI when untreated and a high CI when treated, red); non-responders (a 
Figure 1. Schematic overview of the in silico clinical trial presented in this study. A previously developed 
mechanistic model of murine bone regeneration was adapted to describe the aberrant cellular behavior of cells 
affected by NF1 mutation by altering the corresponding parameter values (inner, blue circle: in silico model). 
As an example, the inner circle shows how a conceptual model (1) of cartilage generation can be translated in a 
schematic (2) and mathematical representation (3). By altering the parameter values, various physiological and 
pathological behaviors can be represented (indicated in green). From the altered in silico model, a cohort of 200 
“virtual subjects,” each representing a different parameter combination, was generated. For each virtual subject 
the bone-healing process was simulated both with BMP treatment and without BMP treatment (outer, green 
circle: in silico clinical trial).
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high CI untreated and with treatment, blue); asymptomatic (a low CI untreated and with treatment, green); and 
responders (high CI when non-treated and a lower CI when treated, black).
Interestingly, unsupervised machine-learning methods (Ward hierarchical clustering) computationally con-
firmed the existence of three classes (Fig. 2E): non-responders (blue), asymptomatic (green), and responders 
(black). The algorithm did not define a separate group of six adverse responders as distinguished by the manual 
method. However, five of these subjects clustered together in the asymptomatic group, and one was placed among 
the non-responders group (blue) by the algorithm. The Ward hierarchical clustering algorithm also classified 
three responder subjects (black) among the asymptomatic (green), which is different from the manual classifi-
cation. Note that these four subjects differently classified by the manual and computational methods all lie very 
close to the previously defined arbitrary cut-off (Fig. 2D).
The virtual clinical trial identified potential biomarkers. Next, we investigated whether the man-
ually defined subject classes have distinctive characteristics that can be used as potential biomarkers to pre-
dict the efficacy of BMP treatment. We focused here on the difference between the responders (black) and the 
non-responders (blue), as these subjects can benefit most from BMP treatment. We first calculated the Spearman 
correlation matrix of the dataset including the 8 NF1 parameters as well as fibrous, cartilage, and bone tissue frac-
tions at different time points to check for highly correlated (redundant) attributes (Fig. 3). Importantly, the results 
showed that the NF1 parameters were uncorrelated. As expected, the CI value was negatively correlated with the 
bone tissue fraction and positively correlated with the fibrous tissue fraction. Similarly, some NF1 parameters 
were correlated with certain tissue fraction outcomes (e.g., Af0, which describes the rate of fibroblastic prolifera-
tion (see Methods), with the amount of fibrous tissue), and the tissue fractions were also not independent.
Using the 8 NF1-related parameter values in data-driven modeling, we determined which parameter was 
most important in predicting stratification between paired subject groups (Table 1, ROC-curves can be found in 
the supplementary material). Note that not all comparisons are balanced, particularly for the adverse responders 
Figure 2. Results of the in silico clinical trial of 200 virtual subjects. (A) Distribution of the CI values of the 
treated and non-treated virtual subjects. (B) Box plot shows that virtual subjects with BMP treatment had 
significantly lower CI values (y-axis). *P < 0.01. (C) Overview of the amount of bony unions with and without 
BMP treatment. (D) Scatterplot of the treated versus non-treated subjects. Using a cutoff CI of 0.5 (gray dashed 
lines), the virtual subjects clustered in four classes: adverse responders (red, n = 6), non-responders (blue, 
n = 47), asymptomatic (green, n = 100), and responders (black, n = 47). (E) Fanned dendrogram of the treated 
versus non-treated subjects, classified using Ward hierarchical clustering. Note that the manually defined classes 
in panel D are also grouped together here.
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with only 6 subjects. Across all paired groups, Pmc, Y11, and Y3cb are important predictors (Table 1, Supplementary 
Figure 1), with mean accuracy values >0.72. Pmc represents the rate of cartilage formation, Y11 signifies osteogenic 
differentiation, and Y3cb denotes endochondral ossification (see Methods). Importantly, when similar analyses 
are performed on scrambled data, a mean accuracy of 0.48 was obtained, and no clear predictors were found 
(Supplementary Figure S1D–F). These data independently validated the accurate stratification of the subject 
groups.
In order to analyze the data on CI in more detail, we looked at the different components constituting the 
CI value, e.g., the amount of fibrous tissue after 49 days and the amount of non-unions (Fig. 4A). Interestingly, 
the box plots show that there was a significant difference in the amount of fibrous tissue present at day 49 after 
treatment for the different subject classes, with significantly less fibrous tissue present in the responding subjects. 
Moreover, the fraction of non-unions is also lower in the responding subjects (Fig. 4B).
Discussion
The clinical literature reports conflicting evidence about the effectiveness of BMP in treating CPT13,14,17,18. It is 
difficult to compare these clinical studies and draw solid conclusions for various reasons. First the surgical pro-
cedures and fixation methods are very heterogeneous, varying between Ilizarov fixation17, intramedullary fixa-
tion14, autologous grafting18, Masquelet technique13, or a combination thereof. Second, some clinical studies are 
performed with rhBMP-718 whereas others use rhBMP-214. Third, the delivery (e.g., mixed with collagen and 
allograft bone18 or the use of a collagen sponge alone14) and the dosage of the rhBMP (e.g., from 3.518 to 12 mg14) 
varied between studies. Fourth, with CPT being an orphan disease, the few case studies with limited follow-up 
of refracture result in a small amount of patient-specific data. Finally, and most importantly, the treated CPT 
patients each have a specific case history with previous treatments, including multiple surgeries and rounds of 
BMP treatment, which makes conclusions hazardous.
Since virtual clinical trials alleviate some of the above mentioned problems, we combined in this study mech-
anistic modeling with data-driven modeling in an investigative in silico clinical trial to determine the (beneficial) 
Figure 3. Graphical display of the Spearman correlation matrix. Note that the NF1 parameters (cf_BC, Af0, F4, 










Responders Y11 (0.91 ± 0.05) Pmc (0.72 ± 0.08)
Pmc, Y3cb 
(0.86 ± 0.05)
Adverse responders Y11, Pmc (0.92 ± 0.05) Y11 (0.96 ± 0.02)
Non-responders Pmc (0.96 ± 0.03)
Asymptomatic
Table 1. The NF1-related parameters with greatest predictive power to differentiate the paired subject groups in 
the virtual clinical triala. aPredictors are as defined in the Methods and based on mean arbitrary units >50 with 
a random forest, binary classification model. Mean accuracy ± standard deviation is given in parentheses and 
were measured across 100 trained random forest models.
www.nature.com/scientificreports/
5Scientific RepoRTs |  (2018) 8:2465  | DOI:10.1038/s41598-018-20737-y
effect of BMP treatment on fracture healing in NF1 subjects. A large in silico trial was designed, simulated and 
analyzed, based on a previously established computational model of murine bone regeneration. Notably, the 
computational model has been previously corroborated in various pathological conditions including small bone 
defects19, large bone defects20,21 and CPT in NF1 subjects16. Although the parameters and the in silico clinical 
results are related through mathematical equations, the set of partial differential equations is very extensive and 
has many non-linear interactions between the variables. As such it is impossible to intuitively predict how the 
parameter values will influence the in silico predictions, here the bone healing outcome. Therefore, in this study, 
we decided to generate an extensive data set in silico and mine it using machine learning approaches.
An important simulation outcome is the CI value, which reflects the degree of severity of CPT. We found that 
the CI value was significantly lower with BMP, compared to no treatment, for the 200 subjects in our in silico 
clinical trial (Fig. 2). Our computational model predicted a wide range (0.01–0.89) of CI values for both treated 
and untreated conditions, reminiscent of the substantial variation in severity of pseudarthrosis, which suggests 
that not all subjects benefit from treatment. The large range of predicted CI values for the non-treated subjects 
is remarkable since the parameter values of the eight factors were mostly varied in one direction with respect 
to the baseline value, thereby biasing the design to a CPT phenotype. By manual thresholding the CI values, 
four distinct subject groups were identified: adverse responders, responders, non-responders and asymptomatic. 
Unsupervised Ward hierarchical clustering confirmed the existence of all classes except the adverse responders, 
although these subjects also clustered together. The existence of four distinct subject groups may explain the 
heterogeneity in the reported clinical outcomes mentioned above, although further research is necessary to con-
firm this subject stratification and find biomarkers thereof, in particular for the small subpopulation of subjects 
predicted to negatively react to the BMP treatment.
It is also noteworthy that the in silico responders (n = 47) have a wide range in the amount of fibrous tissue 
at day 49 (Fig. 4A). The presence of fibrous tissue in the regenerating tissue may correlate to inferior mechanical 
properties and a higher risk for refracture. As such, the computational results seem to confirm the clinical obser-
vation that BMP induces healing but with a substantial refracture risk although this biomechanical hypothesis 
should be investigated further.
In addition to subject stratification, the data-driven modeling techniques allowed us to identify three NF1 
parameters that can accurately predict stratification among paired subject groups (Table 1). With further valida-
tion, these parameters might form the basis of biomarkers for successful BMP treatment. The rate of cartilage for-
mation (Pmc) is a distinguishing factor between the non-responders and the responders. This result corresponds 
to the findings of a previous computational study16 where it was shown that Pmc is a critical determinant for the 
CI value due its important role in the endochondral ossification pathway. Interestingly, Y3cb, a factor representing 
endochondral ossification, was also identified as a predictive NF1 parameter. It should be noted that Pmc and Y3cb 
are not correlated.
While this study focused specifically on the design, execution and analysis of an investigative in silico clinical 
trial for CPT, a pediatric orphan disease, others have used in silico clinical trials to investigate different clinical 
Figure 4. (A) Box plot summarizing the amount of fibrous tissue at day 49 after treatment by subject class. (B) 
Bar plot summarizing the fraction of non-unions per subject class. Adv resp = adverse responders (n = 6); non-
resp = non-responders (n = 47); asymp = asymptomatic (n = 100); resp = responders (n = 47).
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challenges. Clermont et al. constructed a cohort of 1000 virtual trial subjects to evaluate immunomodulatory 
strategies for severe sepsis22 and Qasim et al. have developed 100 individualized finite element models to predict 
the risk of hip fractures in osteoporosis23. Besides refining and partially replacing animals or humans in a clinical 
trial, in silico models can also generate virtual patients with particular characteristics to augment clinical trials, 
which is particularly relevant for trials in children or rare diseases24.
In addition to their value in studying clinical problems, in silico clinical trials offer huge potential in the 
design-discovery phase of biomedical product development. These virtual studies can identify biomarkers, opti-
mize the dosage and duration of therapeutic interventions and patient stratification as well as perform risk and 
safety assessments required for regulatory applications10. For example, Martelli et al. used finite element models 
to perform an extensive risk analysis and robustness assessment of novel epiphyseal hip implants25. Similarly, 
Wilkoff et al. successfully developed a comprehensive modeling framework to provide a robust safety evaluation 
of the lead electrode heating hazard when patients with implanted pacemakers and defibrillators are scanned in 
a magnetic resonance imaging environment26. Kovatchev et al. have established an in silico metabolic model to 
test the safety and limitations of closed-loop control algorithms that link subcutaneous glucose sensors to insu-
lin pumps in an artificial pancreas27. Importantly, the in silico metabolic model has been shown to adequately 
represent glucose fluctuations in type 1 diabetes and has been accepted by the Food and Drug Administration as 
a substitute to animal trials in the preclinical testing of closed-loop control algorithms. Notably, because of the 
increasing interest in the use of in silico models, frameworks and guidelines are being developed to thoroughly 
investigate the reliability of in silico model predictions for regulatory applications28 and in silico clinical trials6,29.
Although the in silico clinical trial presented here offers much insight into treatment of CPT, we recognize 
several limitations. Firstly, the in silico clinical trial considers a cohort of (only) 200 murine subjects in order to 
balance between statistical accuracy and computational feasibility (one simulation requires on average 48 hours 
computing time on one node of a high performance cluster). The virtual CPT subjects were based on a murine 
model of bone regeneration, including a generic murine-based geometry, due to the lack of experimental human 
data and to reduce computational demands. In silico simulations have shown, however, that increasing the fracture 
geometry to human dimensions will proportionally increase the fracture healing time (unpublished data). 
Secondly, the virtual subjects were uniformly sampled across the parameter space which resulted in a large range 
of phenotypes and inherent variability in the data. From the additional data-driven analyses, four subject groups 
were identified but these were not similar in size. Moreover, the group size of the adverse responders was too small 
to draw any statistically significant conclusions. In the future, advanced algorithms, such as bootstrap aggregat-
ing, could be used to tackle the issues related to unequally sized clusters. A larger cohort of subjects could also be 
simulated, with an improved sampling of the group of adverse responders as well as a more refined definition of 
the manually identified groups. Thirdly, the degree of severity of CPT was assessed by the CI, previously defined 
by three phenotypic criteria: the absence of cortical bridging of the defect, the amount of fibrous tissue and the 
amount of fibroblasts16. The results of this clinical trial should be interpreted in light of this definition, which puts 
a lot of importance on the presence of fibroblasts and fibrous tissue.
Nevertheless, the combined mechanistic and data-driven modeling approach allows us to successfully per-
form and analyze an investigative in silico clinical trial, including the identification of subject subpopulations. An 
obvious next step would be to extensively characterize the real patient-specific parameter distributions and the 
corresponding distribution of clinical CI values and compare those with the simulated cohort. However, due to 
the particular nature of the disease (orphan, pediatric), it will be extremely difficult to obtain these distributions 
for a sufficiently high number of patients. As an intermediate proxy, we intend to characterize a number of in 
vitro properties such as trilineage differentiation capacity of NF1-haplodeficient cells and NF1-null cells from 
various donors. Another important step towards a clinical translation of these results is the in vivo validation of 
the in silico predictions in order to find out whether these subject subpopulations truly exist. Moreover, in case 
of discrepancies between the predicted and measured in vivo outcomes, the additional in vivo experimentation 
would allow for the identification of any shortcomings of the computational model, such as particular model 
simplifications (see ref.16 for a more elaborate discussion on model simplifications).
In summary, in silico models and virtual clinical trials are increasingly being explored to tackle the chal-
lenges associated with pediatric diseases and/or orphan diseases. This study demonstrates how mechanistic and 
data-driven modeling are useful tools to simulate and mine data from in silico clinical trials and stratify subject 
populations to improve current treatment strategies. This robust modeling approach can also be employed for 
biomarker identification, optimization of the dosage or of the duration of the proposed intervention. Moreover, 
this study shows the vast potential of in silico medicine technologies as well as their implications for other orphan 
diseases.
Materials and Methods
Design of the in silico clinical trial. The set of 200 virtual subjects was generated from a previously estab-
lished multiscale computational model of murine bone regeneration, which has been corroborated for small bone 
defects19, large bone defects20, and CPT in NF1 subjects16. Although the exact etiology of CPT is still unknown, 
40–80% of CPT patients are carriers of a mutation in the NF1 gene. Also, it has been postulated that double inac-
tivation of the NF1 gene is necessary for the development of pseudarthrosis30,31, and that the relative proportion 
of NF1-haplodeficient cells and NF1-null cells in the pseudarthrosis region will determine the healing outcome. 
To examine the effect of the NF1 mutation on bone-fracture healing, the parameter values of the factors describ-
ing the aberrant cellular behavior of NF1-haplodeficient and NF1-null cells were varied across a wide range in 
the computational model (Table 2) to account for the variable proportion of NF1-haplodeficient and NF1-null 
cells in the pseudarthrosis region. In particular, a larger deviation of the parameter values from the normal case 
represents a higher proportion of NF1-null cells. We focused on the influence of eight factors described in the 
literature as contributors to the poor fracture-healing outcome in CPT patients: increased invasion of fibrous 
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lesion cells (cf,BC)12, increased fibroblastic proliferation (Af0)12, increased fibroblastic differentiation (F4)32, reduced 
osteogenic differentiation (Y11)12,33, reduced endochondral ossification (Y3,cb)12, reduced cartilage formation 
(Pmc)12, increased fibrous tissue formation (Pmf)32, and increased angiogenic growth factor production (Ggvc)12,34. 
Importantly, the computational model focuses on the cellular and biochemical aspects of CPT and implicitly 
assumes that the fracture is sufficiently stabilized to allow bone formation. Hence, mechanoregulatory stimuli 
were not considered in the computational model.
The in silico clinical trial consisted of 200 virtual subjects for which the healing process was simulated both 
with BMP treatment and without treatment. The 200 virtual subjects were generated using the “Design of 
Experiments” (DOE) tool of JMP (SAS Institute Inc., Cary, North Carolina, USA)35,36. DOE (or experimental 
design) is a statistical method that generates an array of combinations of different parameter values within a 
predefined parameter space. A uniform design was chosen since the computational model of bone regeneration 
is highly non-linear. Uniform designs also cope well with the addition and removal of runs. The parameter space 
(Table 2, NF1 range) was determined by varying the parameter values of the eight factors mostly in one direction 
with respect to the normal case, in this way biasing the DOE design to a CPT phenotype. As such, each virtual 
CPT subject had a unique combination of eight parameter values, representing their intrinsic cellular and bio-
chemical properties. Please note that the resection of the fibrous hamartoma, consisting of NF1-haploinsufficient 
and NF1-null cells, is not captured in the in silico model, or in other words, it models the worst-case scenario 
where NF1-null cells are still present in the fracture callus. The computer simulations were performed with these 
parameter combinations, utilizing high-performance computational resources provided by the VSC (Flemish 
Supercomputer Center).
BMP treatment was modeled using one generic osteochondrogenic growth factor (gbc), which represents the 
effect of multiple growth factors present in the fracture callus and released from the BMP sponge as a clinical 
treatment. The influence of this generic growth factor on differentiation is either chondrogenic or osteogenic 
depending on the local oxygen tension. To model the gradual release of BMP from a BMP sponge, implanted 
directly after the occurrence of the fracture, a time-dependent, periosteal boundary condition was simulated 
(Eq. 1):




with τ the time constant of the exponential decay, chosen to be equal to 10 days37,38. ⁎gbc BC,  is equal to the standard 
value of the osteochondrogenic boundary condition (see supplementary material).
The degree of severity of CPT is assessed by the complication index (CI, γ7), which was previously defined in 
ref.16 as a linear combination of the three most prevalent symptoms of CPT (a non-union (γ6), harmatoma (γ4), 






A parameter combination yielding a small CI value reflects a small degree of severity of CPT, or in other 
words, the fracture healing proceeds fairly normally. Conversely, a parameter combination resulting in a large CI 
value represents severely impaired fracture healing and is reminiscent of the CPT phenotype.
Statistical analysis. For the statistical analysis of the CI values with and without BMP treatment, a 
two-sided, paired t-test was performed. To classify subjects based on their CI values with and without BMP 
treatment, we used the Ward hierarchical clustering algorithm (ward.D2, Euclidean distance) from the “stats” 
package implemented in R (version 3.3.1)39. To determine the prediction accuracy of the classification and the 
most important predictors, we created a machine-learning model with the “caret”31 package employing the ran-
dom classification algorithm from the “randomForest” package in R40. The random forest model was trained on 
75% of the data with 10-fold cross-validation41. The accuracy was assessed on the remaining 25% of the data. To 
get sufficient precision, the random forest model was trained 100 times with random splitting of data in training 
and testing data set every time. The same analyses were also performed on scrambled data, obtained with the ran-
domization algorithm from the “picante” package42. The script used to perform the statistical analyses is provided 
in the supplementary material.
Factor Symbol Normal case NF1 range
Invasion time fibroblasts cf,BC 3 0–50
Fibroblastic proliferation Af0 0.1 0.1–10
Fibroblastic differentiation F4 0.01 0.01–1
Osteogenic differentiation Y11 20 0–20
Endochondral ossification Y3,cb 1000 0–1000
Cartilage formation Pmc 0.2 0–0.2
Fibrous tissue formation Pmf 0.2 0.2–10
Angiogenic growth factor 
production Ggvc 10
3 103–105
Table 2. Parameter values of the factors describing the aberrant cellular behavior of NF1-mutated cells.
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